Onxeo S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
11,328.70
57,226.60
33,793.00
29,243.00
14,277.00
11,253
Total Accounts Receivable
4,416.00
4,841.60
7,158.00
6,500.00
15,174.00
7,904
Inventories
3.10
65.20
105.00
184.00
30.00
47
Other Current Assets
684.50
704.90
640.00
941.00
481.00
1,172
Total Current Assets
16,432.40
62,838.30
41,696.00
36,868.00
29,962.00
20,376
Net Property, Plant & Equipment
908.30
711.40
841.00
713.00
344.00
296
Total Investments and Advances
368.50
408.70
106.00
110.00
60.00
3,878
Long-Term Note Receivable
0.50
108.60
-
-
-
-
Intangible Assets
22.80
87,931.60
86,368.00
87,213.00
47,535.00
38,573
Other Assets
-
-
200.00
196.00
172.00
127
Total Assets
17,732.50
151,998.60
129,235.00
125,100.00
78,073.00
63,250
ST Debt & Current Portion LT Debt
91.20
1,629.70
69.00
106.00
130.00
Accounts Payable
4,095.70
6,676.00
6,362.00
9,246.00
5,956.00
Income Tax Payable
132.00
119.00
1,637.00
123.00
234.00
Other Current Liabilities
2,038.00
4,494.50
2,538.00
2,942.00
12,522.00
Total Current Liabilities
6,357.00
12,919.20
10,606.00
12,417.00
18,842.00
Provision for Risks & Charges
456.90
555.20
719.00
637.00
550.00
Deferred Taxes
-
13,805.10
11,357.00
11,895.00
4,094.00
Other Liabilities
3,030.20
2,748.10
3,731.00
6,062.00
4,714.00
Total Liabilities
9,844.10
30,027.60
26,437.00
31,011.00
28,200.00
Common Equity (Total)
7,888.40
121,971.00
102,798.00
94,089.00
49,873.00
Total Shareholders' Equity
7,888.40
121,971.00
102,798.00
94,089.00
49,873.00
Total Equity
7,888.40
121,971.00
102,798.00
94,089.00
49,873.00
Liabilities & Shareholders' Equity
17,732.50
151,998.60
129,235.00
125,100.00
78,073.00

About Onxeo

View Profile
Address
49, blvd. du Général Martial Valin
Paris Ile-de-France 75015
France
Employees -
Website http://www.onxeo.com
Updated 07/08/2019
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA. The company was founded by Gilles Avenard and Dominique Costantini on March 5, 1997 and is headquartered in Paris, France.